[Pharmacologic therapy for inflammatory bowel diseases: hopes, disappointments].

Authors:
S Nikolaus, S Schreiber, U R Fölsch
Year of publication:
2005
Volume:
46
Issue:
5
Issn:
0020-9554
Journal title abbreviated:
INTERNIST
Journal title long:
Der Internist
Impact factor:
0.336
Abstract: 
Because the etiology of inflammatory bowel diseases is unclear, no causative therapy is available. However, pathophysiology of the disease offers a lot of possibilities to disrupt the inflammatory cascade that maintains the inflammatory process. The aim of every therapy is to maintain remission as long as possible and to amend the natural course of the disease. Pharmacotherapy includes 5-Aminosalicylates, glucocorticoids, immunosupressants (methotrexate, azathioprine) as well as specific pharmacologic interventions like monoclonal antibodies directed against TNF-alpha (Infliximab). Important supportive tools are available to improve symptoms like diarrhea and pain. Dietetic treatment and surgical procedures represent important alternatives or supplement pharmacotherapeutic interventions.